



# Brisbane Cancer Conference 2024 Preliminary Program

Thursday, 28th November –  
Friday 29th November 2024  
Brisbane Convention and Exhibition  
Centre

## Welcome

Dear Colleagues,

Welcome to the 11th Annual Brisbane Cancer Conference. With the establishment of Health Translation Queensland as an NHMRC Research and Translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical developments in the diagnosis and treatment of malignant disease.

On Thursday 28th November, the meeting will start 8.00am with Breast, Lung and Prostate Cancer, Survivorship, and Immunotherapy symposia running from 8 – 11pm in the morning. The symposia will be followed by satellite symposia and plenary lectures. Subsequently there will be workshops from 4:30 – 6:30pm.

**The symposium Gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues and patient advocates and consumers from other institutions, the city and Queensland.**

The all-day session on Friday 29<sup>th</sup> November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon. A key session will be lectures by Queensland oncology researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology, and treatment of malignant disease.

Over 1,000 delegates registered for the event last year demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation, our many sponsors, the time and effort of the chairs who put the workshops together as well as Therese and the QUT Cancer and Ageing Research Program (CARP) team.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

**Professor Ken O'Byrne**

**Consultant Medical Oncologist**

Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology

## Day 1

Thursday 28th November, 2024

Registration

Opens 7am

Coffee cart Supported by TRI

Registration opens at 7am

Symposia

8.00 - 11.30 am

Morning tea supported by AstraZeneca

Survivorship

Plaza level, P6

Supported by MSD

CHAIRS: Laurelie Wishart, Harry Gasper

08.00 - Welcome and update from QCCS – Kim Alexander

08.15 - Update on the Queensland Cancer Centre: Shaping survivorship care in Queensland - Glen Kennedy

08.30 - Co-designing post-treatment survivorship care for Queenslanders: A new program to improve social connection and health outcomes in women impacted by cancer - Christina Lowe, Xanthia Bourdaniotis

08.45 - Survivorship Care in Paediatrics: Development of a model of care for end of treatment – the RECOVER Project - Shelley Rumble

09.00 - Survivorship Care in Adults: - My First 70 days as a Survivorship Nurse Navigator - Leilani Way

09.15 - Survivorship in a Shared Care setting: Shared Care for Early Breast Cancer – Toowoomba Hospital experience - Marion Strong

09.30 - Survivorship Care Regional and Rural perspective: Implementing a shared care model to enable regional/rural patients with head and neck cancer to access local speech pathology care - Corey Patterson

09.45 - Survivorship Care in First Nations Queenslanders: Blood cancer survivorship in First Nations Queenslanders - Jodie Jetann, Dr Shafkat Jahan, Gail Garvey

10.00 – Morning tea

10.30 - Panel discussion and workshop: Survivorship care plans: What's their value and can/do we operationalise them?

Panel - Harry Gasper, Sharon Donaldson, Marion Strong, Carla Thamm, Corey Patterson, Leonne Young, Gail Garvey

11.30am Session concluding remarks

11.45 - Break

Breast Cancer

Plaza Level, P7 & 8

Supported by AstraZeneca

Chairs: Peter Simpson, Rik Thompson, Jasotha Sanmugarajah

8.00 - Welcome and Intros

8.05 - Denosumab as Primary prevention of Breast cancer in females with a germline BRCA1 mutation - Christian Singer

8.20 - Identification of breast cancer risk genes which modulate responses to immune mediated destruction - Jonathan Beesley

8.40 - The transformative potential of mRNA cancer vaccines - Seth Cheetham

9.00 - Novel immunotherapeutic targets to treat primary and metastatic breast cancer - Roberta Mazziari

9.20 - Addition of the therapeutic MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial - Christian Singer

10.00 - Morning tea

10.30 - Clinical trials in immune-oncology - Nicole Pringle

10.45 - Antibody Drug Conjugates in Breast Cancer – Rebecca Moor

11.00 - The Enhancing Women's Recovery after Cancer Treatment Program (RECENTRE): A values-based implementation and evaluation - Janine Porter-Steele & Sarah Balaam

11.15 - It's About More Than Sex: Examining Sexual Wellbeing in Younger Women After Breast Cancer- Mackenzie Petie

11.30 - Q&A and concluding remarks

11.45 – Break

## **Prostate Cancer**

**Plaza level, P9**

### **Supported by Janssen**

CHAIR: Chun Gan, Michael Huo

Session 1 – Advancements in clinical Care

8.00 - Radiology: prostate MRI tips, pitfalls and utility post prostatectomy - Sonja Gustafson

8.17 - Medical oncology: - Title - Aaron Hansen

8.34 - Radiation oncology: Salvage SBRT - David Pryor

8.51 - Exercise physiology: ERADICATE trial - Robert Newton

9.08 - Urology: Retzius sparing prostatectomy - Ross Fowler

9.25 - Physiotherapy: Pelvic floor rehab/incontinence - David Cowley

9.42 - Discussion/QA

10.00 – Morning tea (supported by AstraZeneca)

Session 2 - Translational Research

10.30 - Preclinical development of new targeted therapeutic strategy for advanced prostate cancer - Lisa Philp

10.50 - A novel targeted therapy for treatment-emergent anaplastic forms of CRPC - Brett Hollier

11.10 - Inhibition of tumour growth with MetAP2 inhibitor Evexomostat/SDX-7320 in stage-specific models of prostate cancer

11.30 - Q&A and concluding remarks

11.45 - Break

## **Advances in Immuno-Oncology**

**Plaza Level, P10 & P11**

### **Supported by BMS**

CHAIRS: Antiopi Varelias, Kenneth O'Byrne

8.00 - Recent advances in I-O therapy - Rahul Ladwa

8.20 - Update on biomarkers - Kenneth O'Byrne

8.40 - Spatial atlas of I-O mediated dynamics of the tumour draining lymph node - Monika Prelowska

9.00 - Combinations I-O ADC - Adnan Nagrial

9.25 - CD8 T-cell anti-tumour immunity to resolve I-O therapy resistance – Jiajie (Jet) Hou

9.45 - Discussion: Chairs and speakers

10.00 - Morning tea

10.20 - Cancer Vaccines: Principles and Practice - Liam O'Brien BiTES - Laura Tam

10.40 - CAR-T cells solid tumours - Rajiv Khanna

11.00 - CAR-T cells Haematological Malignancies - Andrea Henden

11.20 - CRS and ICANS management from the nurse perspective - Michelle Beutel

11.40 - Q&A and concluding remarks

11.45 – Break

## **Lung Cancer Symposium**

**Sky level, Room 1**

### **Supported by Lung Foundation Australia**

CHAIRS: Henry Marshall, Michelle Murphy

Title: Lung cancer screening: Is Queensland ready yet?  
08.00 - Role out of the Australian Lung Cancer program - Henry Marshall  
08.20 - Pulmonary nodule MDT workflows - Gerry Olive  
08.40 - Imaging assessments for pulmonary nodules - Catherine Jones  
09.00 - When and how to biopsy pulmonary nodules - David Fielding  
09.20 - Engaging the First Nations Population - Zulfiqar Otti  
09.40 - Panel discussion: Screening in Queensland  
10.00 - Morning tea  
10.20 - Clinical trials for Stage I lung cancer – Adnan Nagrieli  
10.35 - Role of radiotherapy in Stage I disease - Catherine Bettington  
10.50 - The surgeon’s perspective - Paul Peters  
11.05 - Diagnostic biomarkers - Chaminde Punyadeera  
11.20 - Q&A and concluding remarks  
11.30 - Break

### **Industry Symposia 12.00-13.30**

#### **Session 1: 12.00 – 12.45**

**Plaza level, P6 - 8**

##### **Satellite Session 1: Sponsored by BMS**

Panel: Linda Denehy, Bryan Chan, Niara Oliveira

Title - ‘Evolving Multidisciplinary Teams (MDTs) and the Impact on Early-Stage Oncology Care: Best Practices in Accelerating Standards of Care’

Presentation - Linda Denehy

Panel discussion

#### **Session 2: 12.45 – 13.30**

##### **Satellite Session 2: Supported by MSD**

Chair: Sandro Porceddu

Title: ‘How are we doing with advanced H&N cancer?’

Presentation – Margie McGrath

Panel discussion: **TBC**

### **Lunch 13.30 - 14.00 supported by BMS & MSD**

#### **Plenary Lectures 14.00 – 16.00**

**Plaza Auditorium**

CHAIRS: Damian Topp, Aniko Cooper

14.00 - Australian Comprehensive Cancer Network for achieving Health Equity - Sabe Sabesan

14.17 - Recent advances in breast cancer genomics - Pete Simpson

14.34 - Updates on Sarcoma – Vladimir Andelkovic

14.51 - Evolution in Care of Early Bladder Cancer - Jeff Goh

15.08 - Brisbane theranostics: the next generation - David Pattison

15.25 - Empowering Survivorship: opportunities for personalised care in the digital age - Makala Castelli

15.42 - Health Consumer in the research cycle, a real-life perspective - Alison Bolton

### **Refreshments: 16.00-16.30**

#### **Parallel Workshops: 16.30-18.00**

##### **Bone and soft tissue tumours**

**Plaza Level, Room 6**

CHAIRS: Vladimir Andelkovic, Philip Rowell

16:30 - Spatial profiling of tumour microenvironment uncovers potential novel combinatorial approach in paediatric rhabdomyosarcoma - Cui (Maxine) Tu

16:45 - Establishment, characterisation and phenotypic profiling of primary osteosarcoma in 2D and 3D matrix environment - Bhatia Sugandha

17:00 - Real World Clinical Utility of Next Generation in AYA Sarcoma Patients in an Australian Sarcoma Specialist Centre - Karan Gupta

17:15 - Tumour Genomic Profiling and Treatment Response Assessment in Sarcoma Patient-Derived Organoid (PDO) Models - Laura Croft

17:30 - Genomics and pathology perspective in sarcoma samples - James Bennett

17:45 - 18:30 - Queensland Sarcoma Stakeholder Meeting – Vladimir Andelkovic

## **Genomics**

**Plaza Level, Room 7**

CHAIRS: Quan Nguyen, Mark Adams, Nic Waddell

16.30 - Mapping the neoadjuvant immunotherapy-associated remodeling of the non-small cell lung cancer tumour microenvironment - Bill Dougall

16.47 – ctDNA monitoring assays in cancer - Paul leo

17.04 – Investigating structural variants and methylation in lung cancer through long-Read Sequencing – Lingehen Lui

17.21 – A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer – Sri Srinivasan

17.38 – Unveiling Cancer's Sweet Secrets: Spatially Resolved Mass Spectrometry Imaging of Glycans in Tumour Microenvironments - Arun Everest

17.55 – Concluding remarks

## **Theranostics**

**Plaza Level, Room 8**

CHAIRS: David Pattison, Kristofer Thurecht

4:30 - Clinical trials landscape in theranostics in Australia - Roslyn Francis

4:50 - Evaluating mRNA delivery using nuclear medicine - James Humphries

5:00 - Developing a new chelator for the rapid and stable complexation of the  $\alpha$ -generators bismuth-212 and lead-212 - Melyssa Grieve

5:10 - Evaluation of a new cancer theranostic for ovarian and bladder cancer - John Hooper

5:20 - Theranostics in 2025: an overview - Nattakorn Dhiantravan

5:30 - Theranostics update from PAH - Stanley Ngai

5:40 - Panel Discussion - The Future of Theranostics in Queensland

5:50 - Final comments and questions

## **GU malignancies**

**Plaza Level, Room 9**

CHAIRS: Niara Oliveira, Jeff Goh, Elizabeth Williams

16.30 - 3D organoids for identifying treatment options and drug development - Elizabeth Williams

16.45 - Caring for patients with a neobladder - nursing and allied health perspectives - Michelle Roberts and David Cowley

17.05 - ADCs and new mechanisms of action in bladder cancer - Niara Oliviera

17.20 - Role of Belzutifan for VHL disease - Simon Wood

17.40 - Adjuvant immunotherapy in Renal Cell Cancer - Jeff Goh

## **Cancer Alliance QOOL Data**

**Plaza Level, Room 10**

Title: Monitoring the impact of cancer on Queenslanders: A comprehensive review of lung, pancreas and Merkel cell.

CHAIR: Euan Walpole

16.30 - Introduction

16.40 - Do patient characteristics influence the first-line chemotherapy regimen for adenocarcinoma of the pancreas? – Euan Walpole

17.00 - Variation in Merkel Cell Carcinoma Outcomes: A Queensland Perspective on a Rare and Aggressive Skin Cancer - Shabnam Gujadhur

17.20 - Clinical Practice Indicators for Queenslanders with NSCLC: How do we compare? - Tracey Guan

17.40 - Treating people with cancer in Queensland and Victoria: National benchmarking starts here – Danica Cossio

## **Clinical trials**

**Plaza Level, Room 11**

Title: Recruitment and retention in Oncology Trials

CHAIRS: Suzanne Elliott, Adam Stoneley

16.30 - Opening remarks - Suzanne Elliott

16.40 - Recruitment/Retention cost considerations for Sponsor, Site and Patients - Stephanie Perkins

16.55 - How do sites identify potential patients - Annabel Webber

17.05 - Challenging eligibility criteria - Amber Ward

17.15 - Issues with recruiting for Ph1 Trials - Corrine Fiveash

17.25 - Challenges of Participant reimbursements - Stephanie Airey

17.35 - Dealing with the disgruntled Trial Participant - Amy Ives

17.45 - Panel discussion - Rebecca Clarke, Rachel Wong

## **Survivorship care co-ordination**

**Sky Level, Room S1**

CHAIRS: Natalie Bradford, Rebecca Packer

16.30 - A UNIQUE study to Understand the experiences and Identify the needs of Queenslanders affected by cancer - Belinda Goodwin

16.45 - The effect of diet on cardiometabolic health outcomes of prostate cancer patients treated with androgen deprivation therapy: A systematic review - Hattie Wright

16.57 - Exercise as part of an interdisciplinary approach to Chemotherapy Induced Peripheral Neuropathy management - Kellie Toohey

17.09 - The barriers, enablers and recommendations for improving access to financial aid when a child has cancer - Megumi Lim

17.21 - Symptom assessment in cancer patients undergoing immunotherapy: Cultural considerations in Arabic-speaking adults with advanced disease - Fatimah Alquzi

17.33 - Does turning into a frog, walking with blue bears or your dead mother's touch help?: Early findings from a psychedelic-assisted supportive care trial for bereaved cancer carers with prolonged grief disorder - Vanessa Beasley

17.48 - Q/A and concluding remarks

## **Advocacy and consumer involvement in cancer care and research**

**Plaza Auditorium**

Alison Bolton, Anita McGrath, Michel IteL

Round Table Discussion

## **Gala Dinner, 7.15pm 'til late**

**Boulevard Room**

## **Brisbane Convention and Exhibition Centre**

**Friday 29th November, 2024**

## **Registration Opens at 7.00 am**

### **Plenary Lectures - 8.00 – 10.00**

**Plaza Auditorium**

CHAIRS: John Prins

08.00am - Tumour environment and therapy in melanoma - Nikolas Haass

08.20am - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse - Colm Keane

08.40 - Tackling HPV malignancies with immunotherapy: cervical cancer - Kathryn Middleton

09.00am - Liver transplant for colorectal liver metastases - Thomas O'Rourke

09.20am - Unlocking early ovarian cancer detection: results from the circulating extracellular vesicles study - Carlos Salomon Gallo

09.40am - Adolescent and Young Adults - Are You Aware? - Rick Walker

## **Refreshments**

### **Parallel Workshops**

**10.30 – 12.00**

#### **Pharmacy Research & Innovation Roundup**

**Plaza Level, P6**

CHAIR: Dan McKavanagh

10.30am - Proactive Risk Factor Screening to Enhance Chemotherapy-Induced Nausea and Vomiting Management: An Oncology Outpatient Pilot Study - Shweta Painumpra

10.47am - From toxicity to recovery: A case report of a patient administered glucarpidase for methotrexate toxicity - Michael Whordley

11.04am - Development and implementation of an Introductory Cancer Care Program: Impacts on knowledge, engagement and retention - Sarah Lumchee

11.21am - Evaluation of Medication Management Education provided to patients in the Oncology Day Unit at Ipswich hospital - Guru Sule

11.38am - Increasing safety for high dose methotrexate infusions - Ashlee Aitken

11.47am - Pegasparginase exposure response analysis - Rachael Lawson

11.56am - Concluding remarks

### **Upper GI and HBP malignancies**

**Plaza level, P7**

CHAIRS: Mark Nalder, Kate Roberts

10.30 - CDCP1 and cholangiocarcinoma - Lash Wickramasuriya

10.42 - Radiomics biomarkers are associated with survival in patients with Oesophageal Cancer - Lauren Aoude

10.54 - Nutrition considerations during treatment for UGI cancer - Kelli Edmiston

11.06 - Medical Oncology Updates in UGI/HPB - Yong Yeung

11.18 - CLDN18 testing in gastric cancer - Jen Borowsky

11.30 - Gastric Fill Protocol: Collaborative planning to reduce toxicity of neoadjuvant - Yang Hwang  
chemoradiotherapy for Oesophageal Cancer

11.42 - Current recruiting GI trials in QLD - Kathy You

### **Brain tumours**

**Plaza Level, P8**

CHAIRS: Bryan Day, Mark Pinkham, Zarnie Lwin, Hamish Alexander

10.30am - Pre-op stereotactic radiosurgery for brain metastases; initial experience - Kimberley Budgen

10.45am - Trial in progress: immunotherapy for recurrent glioblastoma - David Walker

11.00am - Audit of molecular testing for glioblastoma at RBWH - Betty Zhang

11.15am - Suppressing recurrence in sonic hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179 - Michelle Li

11.30am - Enhanced telomerase targeting in glioblastoma via augmented 6-thio-2'-deoxyguanosine - Thomas Crawshaw

11.45 - Key role of Peace of Mind Foundation to provide support for people with brain tumours and their families - Fiona Hassmann

### **3-D Cancer models**

**Plaza Level, P9**

CHAIRS: Lisa Philp, Robert Ju, Nikolas Haass

10:30 - Assessing Immune Response in Melanoma by Generating Tumour-Specific CTLs and Co-Culturing with Spheroids - Yimeng Guan

10:40 - Mechanical manipulation of collagen and hyaluronic acid-based hydrogels for 3D cell studies - Marco Enriques Martinez

10:50 - Cytoskeletal-Golgi Crosstalk During Cellular Migration Through Confined Environments - Christanny Schmidt

11:00 - Vascularisation of human skin organoids for enhanced physiological relevance - Mitchell Mostina

11:10 - Novel 3D patient-derived organoids (PDOs) representing the tumour microenvironment (TME) for optimising precision therapy in metastatic endometrial cancer - Asmerom Sengal

11:20 - Application of *in vitro* 3D Models to Study the Effect of Hypofractionated Radiation Therapy for Patient-Derived Breast Cancer Cells - Son Phan

11:30 - Modelling *KRAS* mutant colorectal cancer in 3D - Bianca Nowlan



11:40 - Modelling the vasculature in disease with 3D microfluidic devices - Tish Esseber

### **Gynae-oncology**

CHAIRS: Carlos Solomon Gallo, Kathryn Middleton

**Plaza Level, P10**

10:30am - Targeting replication stress to improve immune recognition and reduce immunosuppressive in the tumour microenvironment - Brian Gabrielli

10:40am - Epigenetic regulation in ovarian cancer - Jason Lee

10:50am - Cytokines bound to ovarian cancer extracellular vesicles in ascites influence their uptake by receptor-expressing cells, impacting their function - Soumyalekshmi Nair

11:00am - Mesoporous Nanotechnology for Ovarian Cancer Detection - Mostafa Kamal Masud

11:10am - Biobanking at the Mater: a resource for better patient outcomes - Kaltin Ferguson

11:20am - 3D Cancer Models or Gynae-oncology - Serena Gallozzi

11:30am - Safety, feasibility and effect of exercise for women receiving chemotherapy for recurrent ovarian cancer: results from the ECHO-R trial - Sandi Hayes

11:40am - Endometrial cancer translational studies at QCGC research - Eva Baxter

11.50am – Summary: Carlos Salomon

### **Thoracic Malignancies**

**Plaza Level, P11**

CHAIRS: Tim Edwards, Gishan Ratnayake

10.30am - Recent updates on thoracic oncology – Zulfiqar Otti

10.45am - Real World Data for Trial validation and biomarker studies – William Mullally

11.00am - Rationale for PRIME lung study - Margot Lehman

11.10am - Management of oligometastatic disease - Gishan Ratnayake

11.20am - Surgery and opportunities for translational research – Morgan Windsor

11.30am - Research snapshots

- Targeting a novel DNA repair protein in NSCLC - Amila Suraweera
- Unique strategies to reverse EGFR TKI resistance - Mark Adams
- KRAS in NSCLC - Lauren Ashwood

11.45am - Discussion

### **Youth Cancer workshop**

**Plaza Auditorium**

CHAIRS: Rick Walker, Katie Lindeberg

10.30 - Introduction to Queensland Youth Cancer Service - Katie Lindeberg

10.45 - Brain Tumours in the AYA population - Rick Walker

11.05 - Survivorship in AYA Cancer - Sandra Gleaves

11.20 - Loss in the AYA Space - Kylie McPaul & Ainslie Plumb

11.50 - Concluding Statements - Katie Lindeberg

### **Lunch 12.00**

### **Plenary Lectures 12.30-2.00**

**Plaza Auditorium**

CHAIRS: Helen Benham, Bena Brown

12.30 - Multi-Omics: The key to precision oncology - Arutha Kulasinghe

12.50 - De-escalation of immunotherapy: a paradigm shift in patient care - Rahul Ladwa

13.10 - Mesothelioma: A model for Precision Medicine in Oncology - Dean Fennell

13.30 - Impact of exercise on cancer survival - Robert Newton

13.50 - Achieving Cancer Care Equity Aboriginal and Torres Strait Islander Queenslanders - Gail Garvey

### **Refreshments 14.10**

### **Parallel Workshops: 14.30 – 16.00**

#### **Haematology**

**Plaza level, P6**

CHAIRS: Colm Keane, Stephen Boyle

14.30pm - Multiomics analysis of immune checkpoint response in follicular lymphoma - Rakin Chowdhury

14.47pm - Practices and outcomes during a watch and wait approach for follicular lymphoma: a study from the Australasian Lymphoma Alliance - Luani Barge

15.04pm - Managing haematological malignancies in pregnancy - Caroline Wilson

15.21pm - Cellular Therapy in Cancer Care – Experiences from MSKCC Karthik Nath

15.38pm - PICCing the Best PICC- lessons and insights from a multicentre trial and qualitative study - Deanne August

### **Palliative Care**

**Plaza level, P7**

CHAIRS: Ben Gunawan, Philip Goode

14.30pm - Teletrials in Palliative Care - Claire Stokes

14.45pm - Using the Surprise Question in Routine Assessment to Support Best Practice Advance Care Planning and End of Life Care - Arvind Gunasekaran

15.00pm - "MINI steps forwards" - Update on a clinical trial of medicinal cannabis in children with advanced cancer - Anthony Herbert

15.15pm - Cancer, Cannabis & Caregiving: Preliminary Findings from Qualitative Analysis of Carer's Perspectives - Maddison Cuerton

15.30pm - Managing treatment-refractory diarrhoea in palliative care - Trish Kahawita

15.45pm – Discussion and closing remarks

### **GI malignancies**

**Plaza level, P8**

CHAIRS: Vicki Whitehall, Mark Bettington, Matt Burge

14.30pm - The Impact of Clinical Mutation Testing on Management of Gastrointestinal Cancer - Jennifer Borowsky

14.45pm - Development of Patient Derived Organoid Based Predictive Drug Testing for Rectal Cancer - Krystal Lianos

15.00pm - Latest Advances in Immunotherapy for Colorectal and Anal Cancer: Game Changing Updates from ASCO and ESMO - Matthew Burge

15.15pm - Preclinical Data to Clinical Trial Development: Showcasing an Exciting Clinical Research Collaboration - Vicki Whitehall

15.30pm - Liver Transplant for Metastatic Colorectal Cancer - Pramudith Sirimanna

15.45pm – Discussion

### **Multiomics**

**Plaza level, P9**

CHAIRS: Arutha Kulasinghe

14.30 - SpaMTP: integrating spatial metabolomics with spatial transcriptomics - Andrew Causer

14.45 - Immune checkpoint expression in whole slide tissues - Courtney Waller

15.00 - Spatial metabolic profiling in head and neck cancer - Naomi Berrell

15.15 - Spatial interaction mapping of PD-1/PD-L1 - Vahid Yaghoubi Naei

15.30 - Developing an Integrated spatial proteomic analysis pipeline - Rafael Tubelleza

15.45 - Mapping and comparing spatial community features across cancer patients - Feng Zhang

### **Melanoma**

**Plaza level, P10**

CHAIRS: Hannah Neuendorf, Wen Xu, Nikolas Haass

14:30 - Autophagy in MITF-driven phenotypic heterogeneity of melanoma - Gisella Edny

14:40 - Exploring the Genetics of Melanoma Risk Factors - Shanika Jayasinghe

14:50 - TILS and other TOOLS of the trade - Robert Mason

15:00 - Peptide scaffolds as potential tools for Melanoma therapy - Henry Lamb

15:10 - Investigating the tumour environment of melanoma brain metastases - Clémence Belle

15:20 - ROCK-inhibition sensitises dormant melanoma cells to BRAF/MEK inhibitors - Kota Tachibana

15:30 - Neoadjuvant immunotherapy in resectable stage III melanoma - Marcin Dzenis

15:50 - Targeting the BRN2 Transcription Factor in Melanoma - Hannah Neuendorf

**Breast cancer – supported by Daiichi****Plaza level, P11**

CHAIRS: Pete Simpson, Rik Thompson, Jodi Saunas

14.30 – Identifying the risk of breast cancer recurrence from the Queensland Oncology Repository – Meghan Stephensen

14.48 - The differentiation detective: tracking epigenomic regulation to explore the BRCA1-TNBC connection - Anna Alvsaker

15.07 – Using targeted alpha particle therapy for in-situ vaccina – Jodi Saunas

15.25 – Exploiting immunogenic cell death and proteasome inhibition to improve cancer immunotherapy - Davide Moi

15.45 - The immunoregulatory effect of radiotherapy and anti-VISTA in a preclinical model of TNBC - Chelsea Kralik

**Head and neck cancer****Sky level, S1**

CHAIRS: Sarju Vasani, Margaret Mcgrath

14.30pm - Investigating the impact of skull base surgery on nutrition and swallowing outcomes - Joanne Hiatt.

14.35pm - Final analysis of a prospective study evaluating sexual health, facial appearance, and appearance distress in patients with human papillomavirus-associated oropharyngeal cancer patients treated with chemoradiation – Lachlan McDowell

14.42pm - Toxicities and functional impacts of immune check-point inhibitor therapy for head and neck cancer: A scoping review - Nicole O'Donnell

14.47pm - Lymphatic imaging with ICG lymphography for head and neck lymphoedema - Megan Trevethan

14.52pm - Discussion – Treatment toxicity. Can we de-escalate and how?

15.02pm - A tumour-informed ctDNA detection workflow in head and neck cancer patients - Xiaomin (Celeste) Huang

15.07pm - Saliva and Plasma-Derived Small Extracellular Vesicles: Promising Prognostic Biomarkers for Head and Neck Cancers - Abolfazi Jangholi

15.12pm - Discussion Biomarkers – How do we incorporate these in clinical trials?

15.22pm - Lisa Xuehan Lu: Spatial Multi-Omics Analysis of HPV-Positive Head and Neck Cancer: Tumour Oncogenesis and Discovery of Targeted Therapies - Lisa Xuehan Lu

15.27pm - Deep Spatial Profiling of the Head and Neck Tumour Microenvironment for Predictors of Response and Resistance to Immunotherapy – James Monkman

15.32pm - Applications of proteomics to cHNSCC with perineural spread – Jonathan P Helena

15.37pm - Discussion – is more data necessarily better?

**Refreshments: 16.00****Plenary session 16.15 – 17.15****Plaza Auditorium**

CHAIRS: Kenneth O'Byrne, Arutha Kulasinghe

The impact of AI on cancer research

Presenters:


16.15 - Foundation Digital pathology models: From computational pathology to spatial biology - Carlo Bifulco

16.40 - MultiOmics and mesothelioma - Dean Fennell


17.00 - Q&amp;A

**Wine and cheese 17.15 - 18.15**

# Venue Floor Plans



## Plaza Level



## Boulevard Level

